PT  - JOURNAL ARTICLE
AU  - Medeiros, G.X.
AU  - Sasahara, G.L.
AU  - Magawa, J.Y
AU  - Nunes, JPS
AU  - Bruno, F.R.
AU  - Kuramoto, A.
AU  - Almeida, R.R.
AU  - Ferreira, M.A.
AU  - Scagion, G.P.
AU  - Candido, E.D.
AU  - Leal, F.B.
AU  - Oliveira, D.B.L.
AU  - Durigon, E.L.
AU  - Silva, R.C.V.
AU  - Rosa, D.S.
AU  - Boscardin, S.B.
AU  - Coelho, V.P.C.
AU  - Kalil, J
AU  - Santos, K.S.
AU  - Cunha-Neto, E.
TI  - Reduced T cell and antibody responses to inactivated coronavirus vaccine among males and individuals above 55 years old
AID  - 10.1101/2021.08.16.21262069
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.16.21262069
4099  - http://medrxiv.org/content/early/2021/08/23/2021.08.16.21262069.short
4100  - http://medrxiv.org/content/early/2021/08/23/2021.08.16.21262069.full
AB  - Background CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of health care workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinees as compared to convalescent subjects.Methods We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the original SARS-CoV-2 strain, and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a cohort of CoronaVac vaccinees (N=101) and convalescent (N=72) individuals.Findings Among vaccinees, 95% displayed T cell or antibody responses to SARS-CoV-2 as compared to 99% convalescent individuals. However, we observed that among vaccinees, males and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralizing antibody responses as well as antigen-induced IL-2 production by T cells.Interpretation Even though some studies indicated Coronavac helped reduce mortality among elderly people, considering the current dominance of the gamma variant of concern (VOC) and potential increase of the delta VOC, in Brazil, our data support that Coronavac vaccinees above 55 years old Coronavac vaccinees above 55 years old could benefit from a heterologous third dose/booster vaccine to improve immune response and protection.Funding Brazilian Ministry for Science, Technology and Innovation, Sao Paulo State Foundation for Scientific research (FAPESP), JBS S.A.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBrazilian Ministry for Science, Technology and Innovation, Sao Paulo State Foundation for Scientific research (FAPESP), JBS S.A.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All volunteers signed written informed consent and the study was approved by the Ethics Committee of the Hospital das Clinicas da Universidade de Sao Paulo (CAPPesq CAAE30155220.3.0000.0068).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript are available in the manuscript.